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Specific packaging of human immunodeficiency virus type 1 (HIV-1) RNA is attributable to the high affinity of nucleocapsid (NC) sequence of
Gag for the cis-acting RNA packaging signals located within the 5V un-translated region (5V UTR). Interestingly, we have previously reported that
the T12I mutation (named MP2) within SP1 of Gag prevented incorporation of spliced viral RNA into mutated viruses that lacked the stem-loop 1
(SL1) RNA element (also named dimerization initiation site, DIS), suggesting a role for the SP1 sequence in viral RNA packaging. In this study,
we have further tested this activity of MP2 in the context of a variety of mutations that affect viral RNA incorporation. The results showed that
MP2 was able to effectively restrict packaging of spliced viral RNA into viruses containing either NC mutations R10A and K11A or mutated 5V
UTR sequence, such as DGU3 that lacked the 112-GUCUGUUGUGUG-123 sequence of U5, D1 that was deleted of a 27 nt fragment
immediately downstream of the primer binding site (PBS), D(306–325) that had the SL3 RNA element removed and MD2 that was missing the
328-GGAG-331 sequence. As a result, MP2 contributed increased infectivity to the related viruses. Therefore, the MP2 mutation demonstrates a
distinct role in HIV-1 RNA packaging that is neither pertained to the specific viral RNA packaging signal nor to the NC sequence.
D 2005 Elsevier Inc. All rights reserved.Keywords: HIV-1; SP1; Gag; RNA packagingIntroduction
Human immunodeficiency virus type 1 (HIV-1) recruits two
copies of full-length viral RNA into each virion while
excluding the abundant cellular RNA and spliced viral RNA.
Specificity of this process depends on interactions between cis-
acting viral RNA packaging signals located within the 5V un-
translated RNA region (UTR) and the nucleocapsid (NC)
sequence of the Gag protein (Berkowitz et al., 1996). The cis-
acting signals (termed C) are composed of four stem-loop
structures including SL1, SL2, SL3 and SL4 (Baudin et al.,
1993; Berkowitz and Goff, 1994; Berkowitz et al., 1993;0042-6822/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2005.09.011
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1 These authors contributed equally to this research.Clever et al., 1995, 2000; Clever and Parslow, 1997; Harrison
and Lever, 1992; McBride and Panganiban, 1996, 1997;
Sakaguchi et al., 1993; Shubsda et al., 2002). SL2 and SL3
exhibit the highest affinity for NC among these four RNA
elements and represent the primary recognition sites for NC
(Amarasinghe et al., 2000, 2001; Clever et al., 1995; De
Guzman et al., 1998). SL1 shows an affinity for NC 70–80%
lower than SL3 and the binding of SL4 to NC is two orders of
magnitude weaker (Amarasinghe et al., 2001; Shubsda et al.,
2002). SL1 and SL4 may either serve as secondary binding
sites of NC or contribute to viral RNA packaging through other
mechanisms. In the case of SL1, it may promote viral RNA
packaging through acting as an RNA dimerization initiation
signal (DIS) (Laughrea and Jette, 1994; Paillart et al., 1994,
2004; Skripkin et al., 1994). The role of SL4 in RNA
packaging may involve stabilizing the overall structures of
the 5V UTR such that SL2 and SL3 can be properly presented
for NC binding.6) 304 – 314
www.e
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the HIV-1 5V UTR harbors three additional RNA structures
named TAR (Tat transactivation response region), the poly(A)
hairpin and the U5-PBS (primer binding site) complex.
Mutation of these RNA structures also leads to deficient viral
RNA packaging (Clever et al., 1999, 2002; Das et al., 1997;
Harrich et al., 2000; Helga-Maria et al., 1999; Russell et al.,
2002). This negative effect is likely due to a possible
disruption of the overall structure of the 5V UTR, which
results in misfolded RNA packaging signals. Indeed, results of
RNA structure modeling and in vitro biochemical analysis
indicate that the HIV-1 5V UTR is capable of adopting distinct
conformations and that a well-regulated equilibrium between
these conformations controls a number of viral processes
including RNA packaging and dimerization (Abbink and
Berkhout, 2003; Berkhout et al., 2002; Huthoff and Berkhout,
2001; Paillart et al., 2002).
The 5V RNA packaging signals are recognized by NC, which
is a highly basic protein containing two zinc finger motifs
Cx2Cx4Hx4C that are well conserved among retroviral Gag
proteins. The zinc finger motifs specifically interact with the
loop nucleosides of SL2 and SL3 (Amarasinghe et al., 2000;
De Guzman et al., 1998), whereas the basic amino acids,
particularly those located at the N-terminus of NC, play a more
general role in RNA binding through electrostatic interaction
with the phosphodiester groups of ribonucleotides (Amara-
singhe et al., 2000; De Guzman et al., 1998). The specific
interactions between NC and RNA packaging signals underline
the results showing that rescue of the mutated SL1 and SL3
sequences involves compensatory mutations within NC such as
I12V, V13G and T24I (Liang et al., 1999; Rong et al., 2003;
Russell et al., 2002).
In addition to NC, the SP1 region of Gag has been
speculated to affect HIV-1 RNA packaging (Kaye and Lever,
1998). SP1 consists of 14 amino acids located between the
capsid (CA) and NC domains. Deletion of SP1 virtually
abolishes HIV-1 particle production (Krausslich et al., 1995).
This activity of SP1 in Gag assembly may depend on its
involvement in the formation of a putative a-helix across the
CA–SP1 junction (Accola et al., 1998). SP1 also acts as a
molecular switch in morphogenesis of virus particles. For
example, blockage of SP1 removal impairs the generation of
conical cores within virus particles (Wiegers et al., 1998). The
potential role of SP1 in viral RNA packaging was first
suggested by a study in which a chimeric HIV-1/HIV-2 Gag
protein containing the HIV-1 SP1-NC sequence was shown to
recruit higher amounts of HIV-1 RNA into virus particles than
the chimeric Gag harboring HIV-1 NC alone (Kaye and Lever,
1998). Following this observation, we reported that a single
T12I amino acid substitution (named MP2) within SP1
prevented the spliced viral RNA from encapsidation into
DIS-deleted viruses (Russell et al., 2003b). However, it was
unclear whether MP2 is able to execute the same activity in the
context of mutations other than the DIS deletion. To address
this issue, we tested whether the MP2 mutation is able to
inhibit packaging of spliced viral RNA into viruses containing
5V UTR mutations different from DDIS as well as whether thisactivity of MP2 can extend to the rescue of mutations within
the NC region.
Results
The MP2 mutation inhibits packaging of spliced viral RNA into
viruses containing a mutated 5V UTR
Within the HIV-1 5V UTR, there are viral RNA packaging
signals (c) of multipartite property. SL1 (also termed DIS)
represents one element of this complex c site. Deletion of SL1
was compensated by the MP2 mutation in part as a result of
excluding incorporation of spliced viral RNA (Russell et al.,
2003b). To test whether MP2 exerts the same effect on
mutation of c RNA sequences other than SL1, we inserted
the MP2 mutation into four mutated DNA constructs including
DGU3, D1, D(306–325) and MD2 (Fig. 1A). DGU3 lacks the
112-GUCUGUUGUGUG-123 sequence within the U5 region
(Liang et al., 2000; Russell et al., 2002), D1 harbors a deletion
of a 27 nt fragment immediately downstream of the primer
binding site (PBS) (Liang et al., 2000), D(306–325) is missing
the SL3 RNA region (Rong et al., 2003) and MD2 lacks the
328-GGAG-331 sequence following SL3 (Russell et al.,
2003a) (Fig. 1A). Levels of viral RNA packaged into these
viruses were measured in RNase protection assays, the data are
shown in Figs. 1C to F and further summarized in Table 1.
The results showed that the DGU3 virus incorporated
significantly higher amounts of spliced viral RNA than did
the wild-type virus BH10 (Fig. 1C). When the MP2 mutation
was present, only a trace amount of spliced viral RNA was
detected. In the case of the D1 deletion, insertion of the MP2
mutation resulted in significantly diminished levels of spliced
viral RNA within the D1-MP2 virus particles (Fig. 1D).
Interestingly, this effect was not seen for the MNC mutation
that represented the T24I substitution within NC and was able
to rescue the D1 mutated virus (Rong et al., 2001), indicating
that MP2 and MNC rescued D1 through distinct mechanisms
(Fig. 1D). We have previously tested seven amino acids
(including L, M, V, C, D, E and K) at the T12 position of SP1
for their ability to rescue replication of the D1 mutated virus
(Rong et al., 2001). The T12L, T12M and T12V substitutions
exhibited rescuing activity similar to MP2. Consistently, results
of RNase protection assays showed that these three mutations
effectively restricted packaging of spliced viral RNA (Fig. 1D).
In contrast, the T12C, T12D, T12E and T12K mutations,
showing weak or no compensation effect on virus replication
(Rong et al., 2001), did not change the levels of spliced viral
RNA associated with the D1 virus particles (Fig. 1D). These
results reveal a strong correlation between exclusion of spliced
viral RNA from packaging and increased virus infectivity.
SL3 functions as one of the viral RNA packaging signals
(Berkowitz et al., 1996). The D(306–325) mutated virus
lacked the SL3 sequence and consequently, packaged
moderately lower levels of full-length viral RNA concomi-
tant with increased amounts of spliced viral RNA (Fig. 1E).
Two second-site mutations have previously been identified,
named A11V in SP1 and I12V in NC that rescued the
B.B. Roy et al. / Virology 344 (2006) 304–314306D(306–325) deletion (Rong et al., 2003). The results of
RNase protection assays revealed that neither A11V nor
I12V effectively decreased the levels of spliced viral RNA
packaged into D(306–325) (Fig. 1E). We next asked whether
MP2 was able to fix this defect. Indeed, packaging of
spliced viral RNA was significantly reduced within theFig. 1. MP2 restricts packaging of spliced viral RNA into viruses containing a mutat
Seven independent stem-loop structures are illustrated including TAR, the poly(A) ha
DGU3, D1, D(306–325) and MD2 lack viral RNA sequences from nt 112 to 123, 2
highlighted as red letters and further summarized in the text box. The MP2 and MNC
respectively. (B) Diagram of the RNA probes used in RNase protection assays. Th
position refers to the +1 transcription initiation site). Dashed lines represent trans
represent viral genomic RNA (310 nt), spliced viral RNA (288 nt) and total viral RNA
suppresses packaging of spliced viral RNA into the DGU3 virus. Levels of genomi
using RNA probes RPA1 for BH10 and RPA-GU3 for virus DGU3. RNA bands co
shown represent one of three independent experiments. (D) MP2 as well as mutation
the D1 mutated virus. The D1 mutated viral RNA was assessed in RNase protectio
RPA1. (E) MP2, but not MNC, prevents the spliced viral RNA from being packag
D(306–325), D(306–325)-MP2, D(306–325)-MNC and D(306–325)-MP2-MNC w
were determined to monitor virus growth. Mock represents infection performed with
specificity as well as wild-type replication to the MD2 mutated virus. For all viruse
RNA were calculated on the basis of band intensity as determined with help of theD(306–325)-MP2 virus, but not for virus D(306-325)-MNC
that contained the T24I mutation within NC (Fig. 1E).
Consistently, the D(306-325)-MP2 virus exhibited markedly
higher infectivity than D(306–325) itself. These results
suggest that the MP2 mutation rescued the D(306–325)
deletion by employing a mechanism distinct from thated 5V UTR. (A) Depiction of the secondary structures within the HIV-1 5V UTR.
irpin, the U5-PBS structure, SL1, SL2, SL3 and SL4 (Berkhout, 1996). Deletions
00 to 226, 306 to 325 and 328 to 331, respectively. The deleted nucleotides are
mutations denote the T12I substitution in SP1 and the T24I substitution in NC,
e RNA probes consist of viral nucleic acid sequence from nt 164 to 321 (nt
cribed vector sequence. The protected viral RNA fragments are illustrated to
(243 nt) as measured by probe binding to the 3V U3-R RNA sequence. (C) MP2
c and spliced viral RNA molecules were measured in RNase protection assays
rresponding to the genomic, spliced and total viral RNA are indicated. Results
s T12L, T12M and T12V within SP1 restores wild-type packaging specificity to
n assay using the RPA-D1 probe that is 26 nt shorter than the wild-type probe
ed into the SL3-deleted virus D(306–325). Infectivity of the mutated viruses
as measured by infecting MT-2 cells. Levels of RT activity in the supernatants
heat-inactivated wild-type viruses. (F) MP2 restores wild-type RNA packaging
s tested in RNase protection assays, relative levels of viral genomic and spliced
AlphaImager program. The results are summarized in Table 1.
Fig. 1 (continued).
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surprisingly, MP2 also prevented packaging of spliced viral
RNA into the MD2 mutant that lacks the 328–GGAG-331
RNA sequence and, as a result, substantially enhanced
replication of this mutated virus (Fig. 1F).
Taken together, we conclude that the MP2 mutation is able
to correct the defect of excessive packaging of spliced viral
RNA caused by a number of mutations across the 5V UTR.
MP2 rescues the R10A and K11A mutations within NC
Since mutation of NC also causes defective RNA packag-
ing, we wished to test whether the compensation activity of
MP2 could facilitate the rescue of NC mutations. Toward this
end, we mutated two basic amino acids, R10 and K11, at the N-
terminus of NC that have been shown to play an important role
in HIV-1 RNA packaging (Cimarelli et al., 2000a). The DNA
constructs thus engineered were named R10A, K11A and
R10A/K11A (Fig. 2A). The MP2 mutation was then inserted
into each of these DNA constructs to generate R10A-MP2,
K11A-MP2 and R10A/K11A-MP2.
Infectivity of these mutated viruses was measured in
experiments performed with either MT-2 cells, CBMCs or
HeLa-CD4-LTR-h-gal cells (MAGI assays). The results
showed that mutations R10A and K11A significantly decreased
viral replication in both MT-2 and CBMCs, with K11A
exhibiting a more severe defect (Figs. 2B, C). This inhibitory
effect of R10A and K11A on virus replication was not revealed
by the data of MAGI assays (Fig. 2D). This is likely because
the MAGI assays measure the levels of viral Tat proteinproduced by infectious viruses, and the R10A and K11A
mutations abrogated virus replication not through impeding Tat
production. Analysis of RNA levels within virus particles
revealed that the R10A virus packaged as much full-length
viral RNA as did the wild-type BH10, yet contained a
significant amount of spliced viral RNA molecules (Fig. 2E,
Table 2). The K11A mutant packaged slightly lower amounts
of full-length viral RNA and moderately higher levels of
spliced viral RNA than the wild-type virus (Fig. 2E, Table 2).
These data implicated a negative impact of spliced viral RNA
packaging on virus replication.
Interestingly, insertion of MP2 increased the infectivity of
both mutants R10A and K11A to almost wild-type levels in
MT-2 cells (Fig. 2B). This effect of MP2 was also observed in
infection experiments performed in CBMCs albeit not as
pronounced as that seen in MT-2 cells (Fig. 2C). Results of
RNase protection assays showed that MP2 prohibited spliced
viral RNA from being packaged into each of these two mutated
viruses (Fig. 2E, Table 2). Therefore, MP2 rescued R10A and
K11A replication in part through limiting the incorporation of
spliced viral RNA.
In the case of the double mutant R10A/K11A, extremely
low viability was observed in infection assays (Figs. 1B, C).
This severe defect in replication is attributed to a significant
reduction in levels of virion-associated full-length viral RNA
as well as an increase in packaging of spliced viral RNA
(Fig. 2E). Insertion of MP2 suppressed packaging of spliced
viral RNA molecules, yet failed to increase the levels of full-
length viral RNA within virions (Fig. 2E). This persistent
severe defect in viral genomic RNA packaging resulted in
Fig. 1 (continued).
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2B, C).
It has been reported that the R10A/K11A mutation was
rescued by the E21K second-site mutation in NC and that the
adverse effect of R10A/K11A on viral replication was less
pronounced in the context of the I24 instead of the T24 NC
sequence (Cimarelli and Luban, 2001; Cimarelli et al., 2000b;
Krogstad et al., 2002). Indeed, results of our infection
experiments showed that the R10A/K11A-E21K and R10A/
K11A-T24I viruses were viable, albeit still exhibiting delayed
growth kinetics with peak levels of RT activity on days 10
and 11, respectively, as opposed to day 5 for BH10 (Fig. 2B).
The positive effects of E21K and T24I on replication of theR10A/K11A mutated virus were further indicated by the
results of experiments performed in CBMCs and HeLa-CD4-
LTR-h-gal cells (Figs. 2C, D). Interestingly, the R10A/K11A-
E21K and R10A/K11A-T24I viruses packaged markedly
higher levels of full-length viral RNA than did the R10A/
K11A virus; yet, all three viruses contained similar levels of
spliced viral RNA (Fig. 2E, Table 2). These data indicate that
both the E21K and T24I mutations rescued the R10A/K11A
mutated virus through promoting incorporation of full-length
viral RNA. However, persistent packaging of significant
amounts of spliced viral RNA into the R10A/K11A-E21K
and R10A/K11A-T24I viruses resulted in delayed virus
growth.
Table 1
Effects of the MP2 mutation on the packaging of genomic and spliced viral
RNA into viruses containing a mutated 5V UTR
Mutants % Relative levels ofa,b spliced
vs. genomic viral RNA
% genomicb,c
RNA packaging
DGU3 33 T 11 49 T 15












D(306–325) 32 T 6 68
D(306–325)-A11V 28 T 8 69
D(306–325)-I12V 36 59
D(306–325)-A11V-I12V 26 T 5 97
D(306–325)-MP2 5 T 5 91
D(306–325)-MNC 36 T 6 101
D(306–325)-MP2-MNC 4 113
MD2 55 T 12 63 T 11
MD2-MP2 9 T 4 81
BH10 7 T 2 100
a Amount of spliced viral RNA incorporated into virions expressed as a
percentage of genomic RNA packaged.
b All values represent the average from at least two independent experiments,
standard errors are given for mutants that were done in triplicate.
c Viral genomic RNA packaged, as a percentage of wild-type BH10.
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K11A-E21K packaged the same levels of full-length viral
RNA as well as the same amounts of spliced viral RNA and,
in culture, both generated peak levels of RT activity on day
10 (Figs. 2B, E). The same observation was made for viruses
K11A and R10A/K11A-T24I (Figs. 2B, E). These results
further demonstrate a correlation between excessive amounts
of spliced viral RNA within particles and decreased virus
infectivity.
Taken together, these results indicate that MP2 rescues
the R10A and K11A mutations through restricting encapsi-
dation of spliced viral RNA. Yet, its compensation activity
is limited in rescuing the R10A/K11A mutation due to the
inability of MP2 to enhance packaging of full-length viral
RNA.
Discussion
HIV-1 RNA packaging is mediated by specific interactions
between the NC sequence of Gag and the RNA packaging
signals including SL1, SL2, SL3 and SL4 (Berkowitz et al.,
1996). Since RNA packaging occurs prior to virus budding
when Gag precursor proteins start to be cleaved by the viral
protease, the cis-acting RNA packaging signals must be
recognized by NC in the context of the Gag precursor.
Conceivably, the RNA packaging activity of NC may be
affected by other sequences of Gag. In support of this notion,studies have shown that the K18A/R22A mutation within
matrix (MA) severely diminished viral RNA incorporation
(Dupont et al., 1999). This defect was further shown as a result
of sequestration of the mutated Gag as well as full-length viral
RNA within the nucleus. As a second example, the SP1 region
has been implicated in regulating HIV-1 RNA encapsidation
(Kaye and Lever, 1998).
In this study, we demonstrate that one role of SP1 in
viral RNA packaging is to restrict incorporation of spliced
viral RNA into virus particles. This conclusion is based on
the finding that substitution of a single amino acid within
SP1 suppresses packaging of spliced viral RNA into
viruses that contain either mutated RNA packaging signals
within the 5V UTR or mutated NC sequence. With this
ability, MP2 effectively increases infectivity of the mutated
viruses.
The mechanism underlying the involvement of SP1 in viral
RNA packaging is poorly defined, largely due to the lack of
structural information on this spacer region either in the context
of the upstream CA domain (Worthylake et al., 1999) or the
downstream NC sequence (Newman et al., 2004). NC protein
alone harbors an extended and flexible N-terminal region (Lee
et al., 1998; Morellet et al., 1992; Summers et al., 1992).
Notably, upon binding to RNA, the N-terminal sequence
adopts a 3(10) helix that actively participates in RNA-binding,
as shown by the NMR structures of the NC/SL3 and NC/SL2
complexes (Amarasinghe et al., 2000; De Guzman et al., 1998).
Conceivably, this 3(10) helical structure may extend into the
adjacent SP1 region within the Gag precursor. Was this the
case, the SP1 sequence and the N-terminal region of NC may
form a continuous helical structure that contributes to viral
RNA recognition.
The MP2 mutation changes the SP1-NC junction sequence
from ATIMMQ to AIIMMQ. This mutated amino acid
segment displays a slightly higher propensity to adopt a
helical structure based on the results of computer modeling
(data not shown). The long hydrophobic side chain of
isoleucine, in comparison to the short hydrophilic side chain
of threonine, may modify the SP1-NC helical structure in a
way such that defective viral RNA packaging can be
corrected.
How does the MP2 mutation restrict the packaging of spliced
viral RNA? One possibility is that MP2 helps NC to recreate the
high affinity for viral genomic RNA containing mutated RNA
packaging signals. In light of this hypothesis, MP2 is expected to
restore wild-type packaging of full-length viral RNA in concert
with excluding incorporation of spliced viral RNA.However, for
the majority of the mutated viruses investigated in this study,
MP2 alone did not increase the levels of full-length viral RNA.
In other words, MP2 helps to restrict packaging of spliced viral
RNA, but does not stimulate incorporation of full-length viral
RNA.
One explanation for this latter observation is that MP2 may
decrease the binding of Gag to the spliced viral RNA even
though it is unable to confer Gag a higher affinity for the mutated
viral genomic RNA. These spliced RNA species are able to bind
NC since they harbor the first 287 nt of 5V UTR containing four
B.B. Roy et al. / Virology 344 (2006) 304–314310RNA structures including TAR, the poly(A) hairpin, the U5-PBS
complex and SL1. These RNA elements have been shown to be
involved in RNA packaging through a direct or an indirect
mechanism (Andersen et al., 2004; Clever et al., 1999, 2002; DasFig. 2. Rescue of the NC mutations by MP2. (A) Illustration of the R10A, K11A, R1
region. The amino acid sequence of wild-type NC is presented with the mutated resid
cells. Viruses equivalent to 5 ng of p24 were used to infect 5  105 MT-2 cells. Vira
For the purpose of clarity, virus growth curves are presented in two graphs and eac
number of 2  106 cells were infected with viruses equivalent to 50 ng of p24. Viru
(D) MAGI assays to measure virus infectivity in one-round infection. An amount of
LTR-h-gal cells. Infected cells were stained blue with X-Gal and the number was cal
that of the wild-type virus set at 100%. The results are the average of three independe
with mutated and wild-type viruses. As a control, viral RNAwas also prepared from
show higher levels of spliced viral RNA than viral genomic RNA within cells as op
virus particles. The relative amounts of viral genomic and spliced RNA for each vet al., 1997; Harrich et al., 2000; Helga-Maria et al., 1999;
Russell et al., 2002). In particular, SL1 binds NC with a
relatively high affinity (Clever et al., 1995; Shubsda et al., 2002).
In the context of wild-type virus, the affinity of spliced viral0A/K11A, R10A/K11A-E21K and R10A/K11A-T24I mutations within the NC
ues for each mutant highlighted. (B) Replication of various NC mutants in MT-2
l growth was monitored by measuring levels of RT activity in the supernatants.
h graph contains the data for wild-type BH10. (C) Virus growth in CBMCs. A
s production was determined by measuring the RT activity in the culture fluids.
viruses equivalent to 10 ng of p24 were utilized to infect 4  104 HeLa-CD4-
culated to represent virus infectivity. The relative infectivity was expressed with
nt infections. (E) Levels of full-length and spliced viral RNA species associated
transfected COS-7 cells and examined in RNase protection assays. The results
posed to the almost exclusive packaging of viral genomic RNA into wild-type
irus are summarized in Table 2.
Fig. 2 (continued).
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viral RNA for packaging. However, when the packaging signals
or the NC sequence are mutated and, as a result, the binding
between Gag and viral genomic RNA becomes weak, spliced
viral RNA can be incorporated with a relatively high efficiency.
To abrogate this latter event, we hypothesize that the MP2
mutation further diminishes the affinity of Gag for spliced viral
RNA.
In summary, results of this study reveal a distinct property of
the MP2 mutation in restricting incorporation of spliced viral
RNA into a variety of viruses containing either mutated viralRNA packaging signals or mutated NC sequence. This finding




The BH10 infectious HIV-1 cDNA clone was used as the
starting material to generate the following DNA constructs.
The R10A, K11A and R10A/K11A mutations were intro-
Fig. 2 (continued).
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primers: pR10A [(5V-C AAT TTT AGG AAC CAA GCA
AAG ATT GTT AAG-3V (nt 1478 to 1508)], pK11A [(5V-GG
AAC CAA AGA GCG ATT GTT AAG TG-3V (nt 1486
to1510)] and pR10A/K11A [(5V-C AAT TTT AGG AAC
CAA GCA GCG ATT GTT AAG TG-3V (nt 1478 to 1510)]
(the nucleotide positions refer to the first nt of the 5V R
region). PCR was performed using the above primers together
with a reverse primer pNC-A [5V-TTA GCC TGT CTC TCA
GTA CAA TC-3V (nt 1630 to 1608)]. The resultant PCR
products were used as primers in a second round of PCR
together with primer pSph-S [5V-AGT GCA TCC AGT GCA
TGC AGG GCC-3V (nt 977 to 1000)] using BH10 or BH10-
MP2 as template. The final PCR products were digested with
restriction enzymes ApaI and SphI and inserted into the BH10
DNA construct.
To generate antisense riboprobes for use in RNase
protection assays (RPA), DNA fragments were amplified
from BH10, DGU3 (Russell et al., 2002) and D1 (Liang et
al., 2000) proviral DNA, respectively, using primers RPA-S
(5V-CAg ggc ccG AGA GCT GCA TCC GGA G-3V [nt 164Table 2
Effects of the MP2 mutation on incorporation of genomic RNA and spliced
viral RNA into viruses containing mutated NC sequence





R10A 23 T 3 106
R10A-MP2 6 T 1 85 T 5
K11A 23 T 4 84 T 16
K11A-MP2 8 T 1 87 T 4
R10A/K11A 33 T 1 55 T 5
R10A/K11A-MP2 17 T 1 45 T 5
R10A/K11A-E21K 36 T 4 103 T 9
R10A/K11A-T24I 28 T 3 71 T 19
BH10-MP2 6 T 1 102 T 6
BH10 7 T 2 100
a Amount of spliced viral RNA incorporated into virions expressed as a
percentage of genomic RNA packaged.
b Results are the average of three independent experiments.
c Viral genomic RNA packaged, as a percentage of wild-type BH10.to 140]) containing an ApaI restriction site (shown in lower
case), and RPA-A (5V-CCT CCG gaa ttc AAA ATT TTT
GGC G-3V [nt 321 to 297]) bearing an EcoRI restriction site
(shown in lower case), as previously described (Russell et
al., 2003a). The resulting PCR products were digested with
ApaI and EcoRI and inserted into the pBluescript II KS+
cloning vector (Stratagene, La Jolla, CA) that had been cut
with the same enzymes to generate constructs RPA1, RPA-
GU3 and RPA-D1. All primers were purchased from
Invitrogen (Burlington, Ontario, Canada).
Cell culture, transfection and infection
COS-7 and MT-2 cells were grown in Dulbecco’s modified
Eagle’s medium and RPMI 1640 medium, respectively,
supplemented with 10% fetal calf serum. Cord blood
mononuclear cells (CBMCs) were grown in RPMI 1640
supplemented with 10% fetal calf serum and 20 U/ml of
interleukin-2. Transfection of COS-7 cells was performed
using Lipofectamine in accordance with manufacturer’s
instructions (Invitrogen). Levels of HIV-1 p24 (capsid) were
quantified in enzyme-linked immunosorbert assays (Vironos-
tika HIV-1 Antigen Microelisa System; Organon Teknika
Corp., Durham, N.C.).
For infection studies, MT-2 cells (5  105) were
incubated with aliquots of virus equivalent to 5 ng of p24
in 2 ml of medium at 37 -C for 2 h. The cells were then
washed twice with complete RPMI 1640 and maintained in
10 ml of medium. Reverse transcriptase (RT) activity in
culture supernatants was measured at various times to
monitor virus growth. For infection of CBMCs, 2  106
cells were exposed to viruses equivalent to 50 ng of p24.
Culture was fed by fresh CBMCs at 7-day intervals. Growth
of viruses was monitored through measuring RT activity in
culture fluids. To perform MAGI assays (a multinuclear
activation of a galactosidase indicator assay) (Kimpton and
Emerman, 1992), an amount of virus equivalent to 10 ng of
p24 (CA) was used to infect 4  104 HeLa-CD4-LTR-h-gal
cells. Each infection was conducted in triplicate. At 48 h after
infection, the cells were fixed with 1% formaldehyde-0.2%
B.B. Roy et al. / Virology 344 (2006) 304–314 313glutaraldehyde in phosphate-buffered saline and stained with
5-bromo-4-chloro-3-indolyl-h-d-galactoside (X-Gal). Infectiv-
ity was calculated based on the number of blue cells counted
per well.
RNase protection assay
The experiments were performed as described previously
(Russell et al., 2003a). In brief, radiolabeled probes were in
vitro transcribed from BspE1-linearized plasmid DNA using
the T7-MEGAshortscript kit (Ambion Inc., Austin, TX) in the
presence of [a-32P]UTP (ICN, Irvine, CA). The RNA probe
RPA1 was used to assess viral RNA prepared from the wild-
type virus BH10 and the virus mutants containing the NC
mutations, the D(306–325) and the MD2 deletion. The RPA-
GU3, and RPA-D1 probes were employed to study the DGU3,
and D1 mutant viral RNA. RNAwas isolated from viruses and
treated with 10 units of DNase I (Invitrogen) for 30 min at 37
-C to remove any plasmid DNA contamination. An amount of
virion RNA equivalent to 25 ng of p24 antigen was analyzed
using the RPA II kit (Ambion Inc.). Protected RNA fragments
were separated on 5% polyacrylamide-8 M urea gels,
visualized by autoradiography and quantified by digital image
analysis using the AlphaImager v5.5 program.
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